-
1 Comment
SymBio Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 92.4% above its 200 day moving average.
From a valuation standpoint, the stock is 78.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.1.
SymBio Pharmaceuticals Limited's total revenue sank by 21.1% to $654M since the same quarter in the previous year.
Its net income has dropped by 89.7% to $-1B since the same quarter in the previous year.
Based on the above factors, SymBio Pharmaceuticals Limited gets an overall score of 2/5.
| ISIN | JP3383050006 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | TSE |
| CurrencyCode | JPY |
| Target Price | None |
|---|---|
| Market Cap | 5B |
| PE Ratio | None |
| Beta | 0.16 |
| Dividend Yield | None |
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; and C-1101, an antiviral drug BCV injectable and oral formulations against double-stranded DNA viruses. The company was incorporated in 2005 and is based in Minato, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4582.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
